Delayed care due to the coronavirus disease 2019 pandemic has created a lot of uncertainty around alternative payment models (APMs) like the Oncology Care Model (OCM), said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Delayed care due to the coronavirus disease 2019 pandemic has created a lot of uncertainty around alternative payment models (APMs) like the Oncology Care Model (OCM), said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Transcript
There has been a lot of delayed care and cancer diagnoses because of the pandemic. How do you expect this will impact practices participating in the Oncology Care Model and planning to transition to Oncology Care First?
That's a great question. I think it creates quite a bit of uncertainty in the field. I think Medicare has done a really nice job in terms of creating flexibility, particularly on the downside risk components of advance alternative payment models, including OCM. So, it was a very welcome kind of flexibility and relief there, and I think that's given practices space to think about how do they want to transition to the future?
I do think just because of the pandemic, and unfortunately, the current rise in cases, I think it's unclear on what's going to happen with the public health emergency. And in turn, I think that just creates uncertainty, broadly speaking with respect to advanced alternative payment models, in general. So, I think it's a little bit unclear right now, how long this interim period will last. And I think, in turn, it makes evaluation of the models really difficult because, well, having a downside risk component to them, it makes it very difficult for Medicare to figure out what's working what's not.
So, all of this, there's a ton of some pieces. Unfortunately, I think this makes it quite difficult for Medicare to kind of locate and situate what they want to do. But I do think there's potential that we could see an extension of OCM for an additional period of time whether that’s that 6 months, a year—I think it really is going to depend on what the public health emergency looks like. And then that, in turn, obviously will roll into what the next Medicare model in cancer care looks like.
The big change from OCM to OCF is the movement to a bundled payment framework in oncology. Is it possible to even move to that kind of framework if we are still in a pandemic?
So, if we still are in a pandemic, I think it's very difficult to ascertain what's going to happen with respect to risk. So, I think, as long as we have rising cases, as long as there's a public health emergency, I think it's very difficult to ask people in the provider system to absorb risk, because simply the variance is enormously high. Right? We don't really know what's going to happen, I think, when variance is high in any field. Really, what you need is a very large sample size.
And one of the trade-offs you're making in moving to value-based payments or risk-based arrangements, you're moving from payers covering large bodies of patients with large samples to practices that will have much smaller samples. So, they're much more prone to variance, and outlier effects. So, I think it's very difficult for providers to absorb risk outright, during the pandemic.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More